Physician
Aspirus Rhinelander & Tomahawk Hospitals & Clinics, INC.
Aspirus Rhinelander & Tomahawk Hospitals & Clinics, INC. was paid $10.23M by Medicaid between Jan 2018 and Dec 2024, across 274 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 9.1% of everything it billed.
33Billing provider infoASPIRUS RHINELANDER & TOMAHAWK HOSPITALS & CLINICS, INC.
RHINELANDER, WI 54501
RHINELANDER, WI 54501
33aNPI1356391247assigned 05/11/2006
33bProvider typeRadiation Oncology Physician
28Total paid$10.23M
24GClaims550,231
24DCodes billed274
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiation Oncology Physician providers in Wisconsin
Rank by total paid#2 of 6
Median peer was paid$144K
This provider vs. median71×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,281 | $1.53M | |
| 2019 | 83,136 | $1.59M | |
| 2020 | 68,418 | $1.31M | |
| 2021 | 84,298 | $1.40M | |
| 2022 | 83,559 | $1.52M | |
| 2023 | 82,061 | $1.56M | |
| 2024incomplete | 65,478 | $1.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.1% | 26,271 | 23,019 | $933K |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.1% | 7,528 | 5,797 | $833K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.3% | 15,743 | 13,771 | $640K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 13,606 | 11,531 | $530K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.0% | 14,694 | 13,210 | $510K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.9% | 9,548 | 8,634 | $500K |
| 80053 | Comprehensive metabolic panel | 4.5% | 26,939 | 21,444 | $463K |
| 99001 | 4.0% | 13,283 | 10,556 | $412K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 5,191 | 4,505 | $289K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 4,791 | 4,193 | $246K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 4,334 | 2,927 | $244K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 3,806 | 3,457 | $244K |
262 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 29,782 | $232K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.1% | 2,004 | $216K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 2,666 | $202K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 3,605 | $162K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 1,597 | $160K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 10,058 | $158K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 24,063 | $154K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 7,452 | $153K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.5% | 2,413 | $149K |
| 80061 | Lipid panel | <1% | 6,996 | $100K |
| 85610 | <1% | 7,247 | $96K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,225 | $92K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,560 | $92K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,474 | $90K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 996 | $90K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,398 | $80K |
| 81025 | <1% | 4,860 | $73K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,112 | $66K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,069 | $65K |
| 81001 | <1% | 12,999 | $62K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 706 | $61K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,076 | $59K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,538 | $58K |
| 80306 | <1% | 3,789 | $52K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,941 | $52K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,608 | $50K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 519 | $48K |
| 83735 | <1% | 10,409 | $46K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 820 | $45K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 672 | $42K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,152 | $42K |
| 84484 | <1% | 5,566 | $40K | |
| 83880 | <1% | 2,331 | $40K | |
| 84439 | <1% | 3,821 | $39K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 838 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,056 | $36K |
| 87070 | <1% | 1,576 | $35K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 751 | $35K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 1,829 | $31K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 716 | $31K |
| 84145 | <1% | 2,083 | $30K | |
| 86850 | <1% | 2,199 | $28K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 977 | $26K |
| 83690 | <1% | 5,230 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 573 | $25K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 383 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,488 | $23K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 105 | $23K |
| 86140 | <1% | 4,793 | $22K | |
| 76830 | Ultrasound, transvaginal | <1% | 586 | $21K |
| 83605 | <1% | 3,134 | $21K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,966 | $21K |
| 85027 | <1% | 3,126 | $21K | |
| 81003 | <1% | 3,305 | $18K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 465 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,646 | $18K |
| 3008F | <1% | 1,859 | $17K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 576 | $17K |
| 82947 | <1% | 1,137 | $16K | |
| 84702 | <1% | 711 | $16K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,157 | $16K |
| 64615 | <1% | 278 | $16K | |
| 85379 | <1% | 2,169 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 368 | $15K |
| 87040 | <1% | 1,816 | $14K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 224 | $13K |
| 83540 | <1% | 645 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 555 | $12K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 236 | $12K |
| 73630 | <1% | 1,276 | $12K | |
| 85730 | <1% | 3,358 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 775 | $11K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 55 | $11K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 318 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 297 | $10K |
| 96368 | <1% | 202 | $10K | |
| G0378 | Hospital observation service, per hour | <1% | 581 | $10K |
| 64494 | <1% | 86 | $10K | |
| 64493 | <1% | 86 | $10K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 198 | $9K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 160 | $9K |
| 93971 | <1% | 251 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 287 | $8K |
| 80329 | <1% | 1,057 | $8K | |
| 87077 | <1% | 1,052 | $8K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 627 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,923 | $8K |
| 82565 | <1% | 770 | $8K | |
| 85652 | <1% | 2,817 | $8K | |
| 82948 | <1% | 1,343 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,151 | $7K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 69 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 284 | $7K |
| 87807 | <1% | 111 | $7K | |
| 70498 | <1% | 95 | $7K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 98 | $6K |
| 87088 | <1% | 1,203 | $6K | |
| 80076 | <1% | 514 | $6K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 122 | $6K |
| 86618 | <1% | 412 | $6K | |
| 86900 | <1% | 2,185 | $6K | |
| 73564 | <1% | 765 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,007 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 75 | $5K |
| 82043 | <1% | 574 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 276 | $5K |
| 86803 | <1% | 383 | $5K | |
| 70496 | <1% | 74 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,708 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 223 | $4K |
| 87469 | <1% | 214 | $4K | |
| 87484 | <1% | 214 | $4K | |
| 87468 | <1% | 214 | $4K | |
| 86901 | <1% | 2,221 | $4K | |
| 85018 | <1% | 1,068 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 72 | $4K |
| 87186 | <1% | 840 | $4K | |
| 90686 | <1% | 1,116 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 536 | $3K |
| 84703 | <1% | 315 | $3K | |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | <1% | 170 | $3K |
| 82805 | <1% | 174 | $3K | |
| 82950 | <1% | 109 | $3K | |
| 84153 | <1% | 193 | $3K | |
| 76642 | <1% | 83 | $3K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 271 | $3K |
| 73030 | <1% | 699 | $3K | |
| 0012A | <1% | 74 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,877 | $3K |
| 93793 | <1% | 669 | $2K | |
| 82728 | <1% | 108 | $2K | |
| 86592 | <1% | 277 | $2K | |
| 73130 | <1% | 648 | $2K | |
| 64483 | <1% | 14 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 324 | $2K |
| 0011A | <1% | 79 | $2K | |
| 90670 | <1% | 632 | $2K | |
| 83550 | <1% | 399 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 62 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 47 | $2K |
| 82550 | <1% | 419 | $2K | |
| 82465 | <1% | 63 | $2K | |
| 72100 | <1% | 317 | $2K | |
| 73610 | <1% | 498 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 28 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 801 | $2K |
| 64490 | <1% | 14 | $2K | |
| 85007 | <1% | 568 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,760 | $1K |
| 74018 | <1% | 163 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| 87210 | <1% | 87 | $1K | |
| 73502 | <1% | 139 | $1K | |
| 82607 | <1% | 139 | $1K | |
| 70486 | <1% | 37 | $1K | |
| 99442 | <1% | 112 | $1K | |
| 87340 | <1% | 151 | $1K | |
| 90723 | <1% | 306 | $1K | |
| 90715 | <1% | 187 | $931.05 | |
| 82150 | <1% | 110 | $899.93 | |
| 87205 | <1% | 253 | $884.47 | |
| 85014 | <1% | 138 | $858.27 | |
| 73110 | <1% | 152 | $846.88 | |
| 90647 | <1% | 257 | $815.63 | |
| 84450 | <1% | 108 | $780.18 | |
| 99223 | Prolong inpt eval add15 m | <1% | 18 | $766.24 |
| 36591 | <1% | 667 | $765.70 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 65 | $737.81 |
| 82977 | <1% | 133 | $723.67 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 132 | $711.06 |
| 84460 | <1% | 162 | $657.91 | |
| 86762 | <1% | 68 | $644.59 | |
| 90680 | <1% | 189 | $611.77 | |
| 80050 | General health panel | <1% | 105 | $608.17 |
| 74021 | <1% | 129 | $606.88 | |
| 92551 | <1% | 43 | $544.04 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 32 | $538.32 |
| 86308 | <1% | 40 | $526.79 | |
| 99173 | <1% | 28 | $496.53 | |
| 99152 | <1% | 30 | $488.69 | |
| 96376 | <1% | 1,848 | $456.00 | |
| 86787 | <1% | 83 | $451.15 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 66 | $447.09 |
| 83718 | <1% | 62 | $435.35 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 574 | $382.36 |
| 99188 | <1% | 29 | $369.18 | |
| 90685 | <1% | 112 | $363.98 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 13 | $354.40 |
| 93017 | <1% | 13 | $338.59 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,926 | $326.38 |
| 80320 | <1% | 1,541 | $323.26 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,701 | $320.95 |
| 77002 | <1% | 14 | $320.16 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 18 | $316.82 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 141 | $313.23 |
| 90674 | <1% | 133 | $309.29 | |
| 86780 | <1% | 36 | $281.12 | |
| 11721 | <1% | 29 | $276.83 | |
| 82570 | <1% | 67 | $253.65 | |
| V5266 | Battery for use in hearing device | <1% | 49 | $226.85 |
| 99307 | <1% | 44 | $207.84 | |
| 97161 | <1% | 13 | $184.84 | |
| 86703 | <1% | 22 | $172.99 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 208 | $168.29 |
| 72040 | <1% | 18 | $157.94 | |
| 90633 | <1% | 54 | $157.38 | |
| 84550 | <1% | 50 | $131.46 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,749 | $106.60 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,577 | $105.15 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 729 | $103.35 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 765 | $92.73 |
| 73140 | <1% | 14 | $88.48 | |
| 87075 | <1% | 16 | $68.70 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 745 | $66.87 |
| 99441 | <1% | 15 | $65.78 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 12 | $61.24 |
| 84156 | <1% | 19 | $59.59 | |
| 88342 | <1% | 142 | $57.39 | |
| G0008 | Administration of influenza virus vaccine | <1% | 383 | $57.06 |
| 36000 | <1% | 578 | $53.96 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 762 | $50.03 |
| 83615 | <1% | 16 | $43.92 | |
| A0380 | Bls mileage (per mile) | <1% | 13 | $42.89 |
| 74019 | <1% | 59 | $40.98 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 257 | $36.10 |
| 84520 | <1% | 13 | $33.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,511 | $33.19 |
| 73080 | <1% | 29 | $33.12 | |
| 85049 | <1% | 16 | $32.60 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,684 | $30.79 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 478 | $22.55 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 14 | $21.12 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,397 | $19.42 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,297 | $17.82 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,730 | $14.51 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,952 | $12.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,008 | $5.94 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,021 | $5.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 962 | $2.77 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 276 | $2.43 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 47 | $1.81 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 88 | $1.07 |
| A9270 | Non-covered item or service | <1% | 4,414 | $0.56 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 990 | $0.36 |
| 91301 | <1% | 159 | $0.10 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 373 | $0.07 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 775 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 178 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 54 | $0.00 |
| 90662 | 0% | 22 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 35 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 54 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 14 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 65 | $0.00 |
| J3490 | Unclassified drugs | 0% | 263 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 165 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 216 | $0.00 |
| 36416 | 0% | 63 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 42 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 15 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.